Literature DB >> 11224729

Extrapulmonary effects of chronic obstructive pulmonary disease.

N J Gross1.   

Abstract

Although airflow obstruction is the most obvious and most studied manifestation of chronic obstructive pulmonary disease (COPD), it should not be overlooked that COPD, particularly in its later stages, is associated with many extrapulmonary features that contribute to the morbidity, reduced quality of life, and, possibly, mortality of this disease. We review here the literature on skeletal muscle dysfunction, osteoporosis, and weight loss in COPD, with particular attention to possible approaches to their management. Patients with COPD may also have other extrapulmonary effects such as hormonal abnormalities that could probably be corrected, but less is known about them. COPD, therefore, should be regarded as a systemic disorder. Its systemic manifestations should not be overlooked in the overall care of the patient, because there are important ways in which they can be addressed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11224729     DOI: 10.1097/00063198-200103000-00006

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  6 in total

1.  Influence of diaphragmatic mobility on hypercapnia in patients with chronic obstructive pulmonary disease.

Authors:  Hyun Wook Kang; Tae Ok Kim; Bo Ram Lee; Jin Yeong Yu; Su Young Chi; Hee Jung Ban; In Jae Oh; Kyu Sik Kim; Yong Soo Kwon; Yu Il Kim; Young Chul Kim; Sung Chul Lim
Journal:  J Korean Med Sci       Date:  2011-09-01       Impact factor: 2.153

2.  Double deficiency of tetraspanins CD9 and CD81 alters cell motility and protease production of macrophages and causes chronic obstructive pulmonary disease-like phenotype in mice.

Authors:  Yoshito Takeda; Ping He; Isao Tachibana; Bo Zhou; Kenji Miyado; Hideshi Kaneko; Mayumi Suzuki; Seigo Minami; Takeo Iwasaki; Sho Goya; Takashi Kijima; Toru Kumagai; Mitsuhiro Yoshida; Tadashi Osaki; Toshihisa Komori; Eisuke Mekada; Ichiro Kawase
Journal:  J Biol Chem       Date:  2008-07-28       Impact factor: 5.157

3.  Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada.

Authors:  A Papaioannou; W Parkinson; N Ferko; L Probyn; G Ioannidis; E Jurriaans; G Cox; R J Cook; D Kumbhare; J D Adachi
Journal:  Osteoporos Int       Date:  2003-10-09       Impact factor: 4.507

Review 4.  Reversal of chronic obstructive pulmonary disease-associated weight loss : are there pharmacological treatment options?

Authors:  Jean K Berry; Charles Baum
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia.

Authors:  Koen Brusselmans; Veerle Compernolle; Marc Tjwa; Michael S Wiesener; Patrick H Maxwell; Désiré Collen; Peter Carmeliet
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

6.  Trabecular bone score in active or former smokers with and without COPD.

Authors:  Jessica González; Macarena Rodríguez-Fraile; Pilar Rivera; Patricia Restituto; Inmaculada Colina; María de Los Desamparados Calleja; Ana B Alcaide; Aránzazu Campo; Juan Bertó; Luís M Seijo; Teresa Pérez; Javier Zulueta; Nerea Varo; Juan P de-Torres
Journal:  PLoS One       Date:  2019-02-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.